Commissioning and initial validation of Eclipse eMC algorithm for the electron FLASH research extension (FLEX) system for pre‐clinical studies

Abstract

AbstractPurposeTo investigate the feasibility of commissioning the 16 MeV electron FLASH Extension (FLEX) in the commercial treatment planning system (TPS) for biomedical research with cell and mouse models, and in silico treatment planning studies.MethodsTo commission the FLEX system with the electron Monte Carlo (eMC) algorithm in the commercial TPS, radiochromic film was used to measure the vendor‐recommended beam data. Once the beam model was generated for the eMC algorithm, supplemental measurements were collected for validation purposes and compared against the TPS‐calculated results. Additionally, the newly commissioned 16 MeV FLASH beam was compared to the corresponding 16 MeV conventional electron beam.ResultsThe eMC algorithm effectively modeled the FLEX system. The eMC‐calculated PDDs and profiles for the 16 MeV electron FLASH beam agreed with measured values within 1%, on average, for 6 × 6 cm2 and 10 × 10 cm2 applicators. Flatness and symmetry deviated by less than 1%, while FWHM and penumbra agreed within 1 mm for both eMC‐calculated and measured profiles. Additionally, the small field (i.e., 2‐cm diameter cutout) that was measured for validation purposes agreed with TPS‐calculated results within 1%, on average, for both the PDD and profiles. The FLASH and conventional dose rate 16 MeV electron beam were in agreement in regard to energy, but the profiles for larger field sizes began to deviate (>10 × 10 cm2) due to the forward‐peaked nature of the FLASH beam. For cell irradiation experiments, the measured and eMC‐calculated in‐plane and cross‐plane absolute dose profiles agreed within 1%, on average.ConclusionsThe FLEX system was successfully commissioned in the commercial TPS using the eMC algorithm, which accurately modeled the forward‐peaked nature of the FLASH beam. A commissioned TPS for FLASH will be useful for pre‐clinical cell and animal studies, as well as in silico FLASH treatment planning studies for future clinical implementation.